Balo Andrew K 4
4 · DEXCOM INC · Filed Mar 14, 2023
Insider Transaction Report
Form 4
DEXCOM INCDXCM
Balo Andrew K
SVP, Regulatory and Clinical
Transactions
- Disposition to Issuer
Common Stock
2023-03-10$111.40/sh−3,275$364,832→ 59,303 total - Disposition to Issuer
Common Stock
2023-03-10$111.40/sh−2,405$267,915→ 56,898 total - Disposition to Issuer
Common Stock
2023-03-10$111.40/sh−5,990$667,280→ 50,908 total
Holdings
- 30,212(indirect: By Trust)
Common Stock
Footnotes (3)
- [F1]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
- [F2]Included in this number are 20,356 unvested restricted stock units, 13,288 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024.
- [F3]Shares are held by the Balo Family Trust U/A/D 4/6/2006, with respect to which the reporting person is a trustee.